About Us

MedDay is proud to be supported by a group of leading investors who share a collective vision to create a business that delivers medicines of exceptional benefit to patients in areas of high unmet need. In April 2016 MedDay secured €34 Million ($38.5M) of new funding to support the international development of lead candidate MD1003 in multiple sclerosis.